Synergistic FLT3 Mutated Proliferative Disorder Treatment System
Legal Citation
Summary of the Inventive Concept
The present inventive concept integrates crenolanib with AI, IoT, blockchain, and new materials to create a more effective and personalized treatment system for FLT3 mutated proliferative disorders.
Background and Problem Solved
The original patent disclosed the use of crenolanib for treating FLT3 mutated proliferative disorders, but its efficacy was limited by the lack of personalized treatment regimens, inefficient patient data management, and inadequate disease progression monitoring. The new inventive concept addresses these limitations by incorporating distinct technologies to create a more powerful system.
Detailed Description of the Inventive Concept
The new system comprises a crenolanib administration module, an AI-powered disease progression monitoring module, and a blockchain-based patient data management module. This integration enables personalized treatment regimens, real-time monitoring, and secure data management. Additionally, IoT-enabled sensors track patient response, and AI-driven analytics predict optimal dosing and treatment schedules. The composition incorporates nanoparticle-based delivery systems using new materials such as graphene, nanocellulose, or nanostructured lipid carriers, enhancing crenolanib's efficacy and bioavailability.
Novelty and Inventive Step
The new inventive concept is novel and non-obvious because it combines crenolanib with distinct technologies, creating a synergistic system that overcomes the limitations of the original patent. The integration of AI, IoT, blockchain, and new materials provides a unique solution for FLT3 mutated proliferative disorder treatment.
Alternative Embodiments and Variations
Alternative embodiments may include variations in the AI-powered disease progression monitoring module, such as using machine learning algorithms or natural language processing. Other variations may include different nanoparticle-based delivery systems or the incorporation of additional distinct technologies, such as gene editing or immunotherapy.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the pharmaceutical and healthcare industries, particularly in the treatment of FLT3 mutated proliferative disorders. The system's ability to provide personalized treatment regimens, real-time monitoring, and secure data management addresses a significant unmet need in the market.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Oncology, pharmaceutical drug delivery, and medical technology with a focus on targeted cancer therapies, particularly FLT3 mutated proliferative disorders and kinase inhibitor treatments
Person of Ordinary Skill (PHOSITA) Profile
A person with advanced training in pharmaceutical sciences, oncology, and biomedical engineering, possessing expertise in drug development, targeted cancer therapies, and emerging medical technologies including AI, IoT, and advanced drug delivery systems
Obviousness Rationale
A PHOSITA would recognize that integrating digital technologies and advanced drug delivery systems with existing targeted cancer therapies represents a predictable evolution of treatment approaches. The combination of crenolanib with AI-driven monitoring, IoT sensors, and nanoparticle delivery systems follows established patterns of medical technology innovation. These extensions would be considered obvious improvements that leverage known technological capabilities to enhance treatment precision and efficacy.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,546 |
|---|---|
| Title | Crenolanib for treating FLT3 mutated proliferative disorders relapsed/refractory to prior treatment |
| Assignee(s) | Arog Pharmaceuticals, Inc. |